Nurses’ roles in preventing cardiotoxicity from Trastuzumab drug in HER-2 breast cancer patients
Article Sidebar
Main Article Content
Abstract
Currently, many different types of cancer had been treated with targeted therapy including HER-2 positive breast cancer. Targeted therapy is specific option for gene and protein expression of individual cancer cells. The most common drug used is Trastuzumab. The use of Trastuzumab drug, has the advantage in increasing survival rate for 10 years, but its adverse effect of cardiotoxicity, can be found among some patients. Therefore, the medical personnel must assess and monitor patients carefully during the treatment. Nurses could also prevent this adverse effect by providing proper discharge education on dietary, physical activity, follow-up coming for checking cardiac function and self-observation on warning signs and symptoms of cardiotoxicity in order to reduce severe complications e.g. congestive heart failure. As a result, these can increase quality of life in patients, reduce hospital length of stay as well as hospital cost.
Article Details
References
กนกวรรณ ปะนะตา, ผ่องศรี ศรีมรกต, เกศรินทร์ อุทริยะประสิทธิ์ และสืบวงศ์ จุฑาภิสิทธิ์. (2561). ผลของ
โปรแกรมส่งเสริมการรับรู้สมรรถนะแห่งตนและแบบแผนการวางแผนชีวิตในผู้รอดชีวิตจากมะเร็งเต้านม
ในระยะระหว่างการรักษา. วารสารพยาบาลทหารบก. 20(1), 197-206.
จิณพิชญ์ชา มะมม. (2551). ความก้าวหน้าในการดูแลรักษาผู้ป่วยมะเร็งเต้านม. วารสารสภาการพยาบาล. 23(2),
-25.
American Cancer Society. (2019 a). How common is breast cancer?. Retrieved July 5, 2019, from
https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html
American Cancer Society. (2019 b). Targeted therapy for breast cancer. Retrieved July 5, 2019, from
https://www.cancer.org/cancer/breast-cancer/treatment/targeted-therapy-for-breast-cancer.html
American Cancer Society. (2019 c). Living as a breast cancer survivor. Retrieved July 5, 2019, from
https://www.cancer.org/cancer/breast-cancer/living-as-a-breast-cancer-survivor/follow-up-care-
after-breast-cancer-treatment.html
American Heart Association. (2019). Classes of heart failure. Retrieved August 1, 2019, from
https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure
Asif, H. M., Sultana, S., Ahmed, S., Akhtar, N., & Tariq, M. (2016). HER-2 positive breast cancer -a Mini-
Review. Asian Pacific Journal of Cancer Prevention, 17(4), 1609-1615.
Balic, M., Thomssen, C., Würstlein, R., Gnant, M., & Harbeck, N. (2019). St. Gallen/Vienna 2019: A brief
summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care,
(2), 103-110.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics
: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA: A Cancer Journal for Clinicians, 68(6), 394-424.
Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., . .
Jackisch, C. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive
early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial. Lancet (London,
England), 389(10075), 1195-1205.
Curigliano, G., Burstein, H. J., Winer E.P., Gnant, M., Dubsky, P., Loibl, S., . . . Xu, B. (2017). De-escalating
and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus
Conference on the primary therapy of early breast cancer 2017. Annals of Oncology, 28(8), 1700-1712.
Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015). Breast cancer intrinsic subtype
classification, clinical use and future trends. American Journal of Cancer Research, 5(10), 2929-2943.
El-Sherbeny, W. S., Sabry, N. M., & Sharbay, R. M. (2019). Prediction of trastuzumab-induced cardiotoxicity
in breast cancer patients receiving anthracycline-based chemotherapy. Journal of Echocardiography,
(2), 76-83
Farvid, M. S., Chen, W. Y., Rosner, B. A., Tamimi, R. M., Willett, W. C., & Eliassen. A. H. (2019). Fruit and
vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow-up.
International Journal of Cancer, 144(7), 1496-1510.
Genuino, A. J., Chaikledkaew, U., The, D. O., Reungwetwattana, T., & Thakkinstian, A. (2019). Adjuvant
trastuzumab regimen for HER2-positive early-stage breast cancer: A systematic review and meta-
analysis. Expert Review of Clinical Pharmacology, 12(8), 815-824.
Guarneri, V., Lenihan, D. J., Valero, V., Durand, J. B., Broglio, K., Hess, K. R., . . . Esteva, F. J. (2006).
Long-term cardiac tolerability of Trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer
Center experience. Journal of Clinical Oncology, 24(25), 4107-4115.
Jacquinot, Q., Meneveau, N., Chatot, M., Bonnetain, F., Degano, B., Bouhaddi, M., . . . Mougin, F. (2017).
A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at
months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by
trastuzumab: Design of the CARDAPAC study. BioMed Central Cancer, 17(1), 1-11.
Jawa, Z., Perez, R. M., Garlie, L., Singh, M., Qamar, R., Khandheria, B. K., . . . Shi, Y. (2016). Risk factors of
trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine, 95(44), e5195-e5195.
Jones, L. W., Habel, L. A., Weltzien, E., Castillo, A., Gupta, D., Kroenke, C. H., . . . Caan, B. J. (2016).
Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. Journal of
Clinical Oncology, 34(23), 2743-2749.
Kong, Y. W., Baqar, S., Jerums, G., & Ekinci, E. I. (2016). Sodium and its role in cardiovascular disease –
The debate continues. Frontiers in Endocrinology, 7(164), 1-17.
Kreiter, E., Richardson, A., Potter, J., & Yasui, Y. (2014). Breast cancer: Trends in international
incidence in men and woman. British Journal of Cancer, 110(7), 1891-1897.
Lee, M. H., Yee, J., Kim, Y. J., Moon, J. Y., Kim, J. H., Rhie, S. J., & Gwak, H. S. (2017). Factors for time to
trastuzumab-induced cardiotoxicity in breast cancer patients. Medical Oncology, 34(12), 199.
Limon-Miro, A. T., Lopez-Teros, V., & Astiazaran-Garcia, H. (2017). Dietary guidelines for breast cancer
patients: A critical review. Advances in Nutrition, 8(4), 613-623.
Masoud, V., & Pagès, G. (2017). Targeted therapies in breast cancer: New challenges to fight against
resistance. World Journal of Clinical Oncology, 8(2), 120-134.
Maximiano, S., Magalhães, P., Guerreiro, M. P., & Morgado, M. (2016). Trastuzumab in the treatment of
breast cancer. BioDrugs, 30(2), 75-86.
Moss, L. S., Starbuck, M. F., Mayer, D. K., Harwood, E. B., & Glotzer, J. (2009). Trastuzumab-Induced
cardiotoxicity. Oncology Nursing Forum, 36(6), 676-685.
National Cancer Institute. (2013). Cancer in Thailand Volume VII, 2007-2009. Retrieved July 22, 2019,
from http://www.nci.go.th/th/cancer_record/cancer_rec1.html
National Cancer Institute. (2015). Cancer in Thailand Volume VIII, 2010-2012. Retrieved July 22, 2019,
from http://www.nci.go.th/th/cancer_record/cancer_rec1.html
National Cancer Institute. (2018). Cancer in Thailand Volume IX, 2013-2015. Retrieved July 22, 2019
from http://www.nci.go.th/th/cancer_record/cancer_rec1.html
National Comprehensive Cancer Network. (2019). Exercise during cancer treatment. Retrieved July 22, 2019,
from https:// www.nccn.org/patients/resources/life_with_cancer/exercise.aspx
Ohtani, K., Ide, T., Hiasa, K. I., Sakamoto, I., Yamashita, N., Kubo, M., & Tsutsui, H. (2019).
Cardioprotective effect of renin-angiotensin inhibitors and beta-blockers in trastuzumab-related
cardiotoxicity. Clinical Research in Cardiology, 108(10), 1128-1139.
Onitilo, A. A., Engel, J. M., & Stankowski, R. V. (2014). Cardiovascular toxicity associated with adjuvant
trastuzumab therapy: Prevalence, patient characteristics, and risk factors. Therapeutic Advances in Drug
Safety, 5(4), 154-166.
Padegimas, A., Clasen, S., & Ky, B. (2019). Cardioprotective strategies to prevent breast cancer therapy-
induced cardiotoxicity. Trends in Cardiovascular Medicine, 30(1), 22-28.
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., . . . Lancellotti, P. (2014).
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy:
A report from the American Society of Echocardiography and the European Association of
Cardiovascular Imaging. Journal of the American Society of Echocardiography, 27(9), 911-939.
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., . . . Ganz,
P. A. (2016). American Cancer Society/American Society of Clinical Oncology Breast Cancer
Survivorship Care Guideline. CA: A Cancer Journal for Clinicians, 66(1), 43-73.
Schmitz, K. H., Courneya, K. S., Matthews, C., Demark-Wahnefried, W., Galvao, D. A., Pinto, B. M., . . .
Schwartz, A. L. (2010). American College of Sports Medicine roundtable on exercise guidelines for
cancer survivors. Medicine & Science in Sports & Exercise, 42(7), 1409-1426.
Scott, E., Daley, A. J., Doll, H., Woodroofe, N., Coleman, R. E., Mutrie, N., . . . Saxton, J. M. (2013). Effects
of an exercise and hypocaloric healthy eating program on biomarkers associated with long-term
prognosis after early-stage breast cancer: A randomized controlled trial. Cancer Causes & Control,
(1), 181-191
Tai, W., Mahato, R., & Cheng, K. (2010). The role of HER2 in cancer therapy and targeted drug delivery.
Journal of Control Release,146(3), 264-275.
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer
statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 87-108.
Wirtz, P., & Baumann, F. T. (2018). Physical activity, exercise and breast cancer - What is the evidence for
rehabilitation, aftercare, and survival? A Review. Breast Care, 13(2), 92-100.